GERN · Geron Corporation

Commercial-stage biotech launching imetelstat (Rytelo) in lower-risk MDS

Risiko 7/10 · ELEVATED · launch · $1.45 ▼ 2.03%

Kennzahlen

• Price $1.45
• Market cap $930.2M
• P/E (ttm) n/a
• Div yield none
• 52-wk range $1.04 – $2.01

Wichtigste Risiken

• Single-product (Rytelo) commercial dependence (Shareholders) — EXTREME
• Launch ramp / reimbursement uncertainty (Revenue) — HIGH
• Financing & dilution if uptake disappoints (Existing holders) — HIGH
• Competition in MDS/myelofibrosis space (Market share) — MED

Fazit

A binary biotech whose long-awaited drug approval shifts the risk from clinical failure to commercial execution on one asset.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.